Trial Profile
An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Fulvestrant
- Indications Ductal carcinoma; Early breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Atossa Therapeutics
- 14 Aug 2020 Status changed from recruiting to discontinued.
- 11 Oct 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 11 Oct 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.